MUFEMILAST (ORAL PDE4 INHIBITOR) FOR ULCERATIVE COLITIS: OPEN-LABEL EXTENSION RESULTS AT 24 WEEKS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP INDUCTION PHASE II CLINICAL TRIAL

Authors
Category Primary study
ConferenceDigestive Disease Week 2026, DDW 2026
Year 2026
This article has no abstract
Epistemonikos ID: 11f15cc1da26e5c400c1ed6ef97def86b3e44434
First added on: Sep 12, 2026